On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.

On the news front, the company has conducted consecutive buybacks over recent sessions, repurchasing approximately 6.465 million shares between June 18 and June 23, spending around HKD 199 million. Year-to-date, the company has executed 14 buybacks totaling 34.218 million shares at a cumulative cost of HKD 1.072 billion, signaling management confidence in intrinsic value.

Meanwhile, WuXi-affiliated enterprises have announced a combined maximum buyback scale of RMB 5.5 billion. The broader CXO sector extended its rally, supported by innovative drug valuations at historical lows, recovering industry investment and financing activity, and strong overseas drug licensing momentum. Within the Life Sciences Tools and Services sector, Insilico rose 12.7%, WuXi XDC rose 4.51%, and WuXi AppTec rose 3.6%, demonstrating significant sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)